Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tetsuya Hosaka

Showing results (281-290 of 306) with videos related to

Pageof 31
Sort By:
Hepatology International|July 24, 2015
Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitisYusuke Kawamura, Satoshi Saitoh, Yasuji Arase, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology|July 12, 2020
Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonographyNobuhiko Ogasawara, Satoshi Saitoh, Fumitaka Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 9, 2023
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictorsNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 16, 2023
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver diseaseNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Internal Medicine (Tokyo, Japan)|May 6, 2026
Serum microRNA-122 Is Associated with the Therapeutic Response to Diet and Exercise Therapy in Patients with Steatotic Liver DiseaseYasuka Eriksson, Norio Akuta, Shigeki Yamamoto, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2020
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysisCheng-Hao Tseng, Yao-Chun Hsu, Tzu-Haw Chen, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 30, 2012
Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patientsFumitaka Suzuki, Yoshiyuki Suzuki, Hitomi Sezaki, et al.
Internal Medicine (Tokyo, Japan)|September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with LenvatinibKayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Pageof 31

Showing results (281-290 of 306) with videos related to

Sort By:
Pageof 31
Hepatology International|July 24, 2015
Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitisYusuke Kawamura, Satoshi Saitoh, Yasuji Arase, et al.
Oncology|June 17, 2021
Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib TreatmentYusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Clinical Journal of Gastroenterology|July 12, 2020
Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonographyNobuhiko Ogasawara, Satoshi Saitoh, Fumitaka Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 9, 2023
Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictorsNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 16, 2023
Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver diseaseNorio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, et al.
Internal Medicine (Tokyo, Japan)|May 6, 2026
Serum microRNA-122 Is Associated with the Therapeutic Response to Diet and Exercise Therapy in Patients with Steatotic Liver DiseaseYasuka Eriksson, Norio Akuta, Shigeki Yamamoto, et al.
The Lancet. Gastroenterology & Hepatology|October 2, 2020
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysisCheng-Hao Tseng, Yao-Chun Hsu, Tzu-Haw Chen, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 30, 2012
Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patientsFumitaka Suzuki, Yoshiyuki Suzuki, Hitomi Sezaki, et al.
Internal Medicine (Tokyo, Japan)|September 23, 2020
Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with LenvatinibKayoko Kasuya, Yusuke Kawamura, Masahiro Kobayashi, et al.
Internal Medicine (Tokyo, Japan)|September 13, 2021
Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib TreatmentNozomu Muraishi, Yusuke Kawamura, Masahiro Kobayashi, et al.
Pageof 31